Detail akcie Clinvel Phrmctls online

Business Summary: Clinuvel Pharmaceuticals Ltd is a biopharmaceutical company. The Company is focused on developing and providing treatments for patients with a range of severe genetic and skin disorders. It is focused on developing and commercializing SCENESSE as a preventative therapy to photo-protect patients with erythropoietic protoporphyria (EPP). It is also focused on developing and commercializing SCENESSE as a combination therapy with narrowband ultraviolet B (NB-UVB) phototherapy for patients with vitiligo. Its pipeline includes research and development into a pediatric formulation of SCENESSE; SCENESSE for adult vitiligo patients; SCENESSE for adult patients with VP; products based on melanocortin analogues CUV9900 and Parvysmelanotide (VLRX001) and a range of over the counter products for general photoprotective application.
Financial Summary: BRIEF: For the six months ended 31 December 2019, Clinuvel Pharmaceuticals Limited revenues remained flat at A$9.8M. Net income decreased 74% to A$1.1M. Revenues reflect Reimbursements received increase of 35% to A$2.6M, Commercial sales of goods increase of 5% to A$7.4M, Total interest income increase of 23% to A$309K, also reflect Total other income (loss) decrease from A$525K to -A$480K.